NASDAQ:CRSP CRISPR Therapeutics Q1 2025 Earnings Results & Report $40.19 +0.04 (+0.10%) Closing price 04:00 PM EasternExtended Trading$40.78 +0.59 (+1.47%) As of 07:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. CRISPR Therapeutics missed analyst earnings expectations in its Q1 2025 results, released May 6, 2025. The company reported EPS of -$1.58 versus the -$1.27 consensus estimate. Revenue increased 71.6% year over year. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2025Report DateMay 6, 2025TimeAfter Market ClosesConference Call12:30 PM ET CRISPR Therapeutics EPS ResultsActual EPS-$1.58Consensus EPS -$1.27Beat/MissMissed by -$0.31One Year Ago EPS-$1.43EPS Beat Rate4 of last 8 quartersCRISPR Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue Growth+71.60%Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) CRISPR Therapeutics Q1 2025 Earnings FAQ Did CRISPR Therapeutics beat earnings estimates for Q1 2025? CRISPR Therapeutics (NASDAQ:CRSP) reported earnings of -$1.58 per share for Q1 2025, missing the consensus estimate of -$1.27. The report was announced on Tuesday, May 6, 2025. CRISPR Therapeutics Earnings HeadlinesCRISPR Therapeutics (CRSP) Flags Early CTX310 And Zugo Cel Wins In Two Big MarketsNovember 18 at 7:17 AM | finance.yahoo.comCRISPR Therapeutics (CRSP) Stock Could Be Above Fair Value On Its 50% Five Year FallNovember 18 at 7:17 AM | finance.yahoo.comELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th. A free Masterclass claims to reveal what Musk filed with regulators and why he's working to keep it quiet.November 18 at 1:00 AM | Paradigm Press (Ad)Is CRISPR Therapeutics (CRSP) Undervalued As CTX310 Data Meets a Share Price Slide?November 18 at 7:17 AM | finance.yahoo.comCRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should KnowNovember 17 at 9:16 AM | finance.yahoo.comSeawolf Therapeutics, Inc. announced that it has received $100 million in funding from a group of investorsNovember 16 at 7:37 AM | marketscreener.comMSee More CRISPR Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like CRISPR Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CRISPR Therapeutics and other key companies, straight to your email. Email Address About CRISPR TherapeuticsCRISPR Therapeutics (NASDAQ:CRSP) is a biotechnology company focused on developing gene-based medicines using CRISPR/Cas9, a gene-editing technology that can make targeted changes to DNA. Founded in 2013, the company is headquartered in Zug, Switzerland, and maintains U.S. operations in Cambridge, Massachusetts. Its lead product, Casgevy (exa-cel), was developed with Vertex Pharmaceuticals for people with sickle cell disease and transfusion-dependent beta thalassemia. It was the first therapy based on CRISPR gene editing to receive regulatory approval. The companies share responsibilities for developing and commercializing Casgevy in authorized markets. Beyond Casgevy, CRISPR Therapeutics is advancing research programs in areas including cancer, autoimmune disease and in vivo gene editing. The company is led by CEO Samarth Kulkarni.View CRISPR Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes ShapeGeneral Motors Faces a Cost Squeeze as Factory Automation Takes Center StageNVIDIA's Earnings Were Strong, But Can the Next CEO Keep the Momentum Going?5 Consumer Discretionary Plays Showing Strength During the Tech Sell-OffAMD Bets $8.2B on Physical AI: Could Robotics Be Its Next Growth Frontier?Viking’s Low-Water Miss Looks Like a Buy-the-Dip OpportunityDisney Has the Magic Touch: Dividend Growth and Buybacks Could Fuel a Breakout Upcoming Earnings NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026)Ross Stores (11/19/2026)Walmart (11/19/2026)Intuit (11/19/2026)Hewlett Packard Enterprise (11/23/2026)Medtronic (11/24/2026)Analog Devices (11/24/2026)Autodesk (11/24/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.